UK trial investigates whether antibiotics could cut miscarriage likelihoodUK researchers are beginning a trial investigating whether a course of antibiotics prior to conceiving could cut likelihood Share XUK trial investigates whether antibiotics could cut miscarriage likelihoodhttps://pharmaphorum.com/news/uk-trial-investigates-whether-antibiotics-could-cut-miscarriage-likelihood/
Merck & Co in pole position for Ebola vaccine approval as FDA begins reviewThe FDA is to review Merck & Co’s Ebola vaccine, giving the US pharma a chance to grab Share XMerck & Co in pole position for Ebola vaccine approval as FDA begins reviewhttps://pharmaphorum.com/news/fda-to-review-merck-cos-ebola-vaccine/
ViiV’s injection still suppresses HIV when taken every two months – studyGSK’s ViiV Healthcare joint venture has announced data backing an injection taken that can suppress the HIV virus Share XViiV’s injection still suppresses HIV when taken every two months – studyhttps://pharmaphorum.com/news/viivs-injection-still-suppresses-hiv-when-taken-every-two-months-study/
Not-for-profit gets tuberculosis drug approved ahead of big pharmaThe FDA has approved a new drug to treat certain types of multi-drug resistant tuberculosis – but it’s Share XNot-for-profit gets tuberculosis drug approved ahead of big pharmahttps://pharmaphorum.com/news/not-for-profit-tb-alliance-gets-new-tb-drug-approved/
Gilead’s R&D chief to step down as new CEO O’Day rings the changesGilead’s chief scientific officer, John McHutchison is to leave the company at the beginning of next month during Share XGilead’s R&D chief to step down as new CEO O’Day rings the changeshttps://pharmaphorum.com/news/gileads-rd-chief-to-step-down-as-new-ceo-oday-rings-the-changes/
Roche’s Tamiflu successor on target in phase 3 trialA trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, Share XRoche’s Tamiflu successor on target in phase 3 trialhttps://pharmaphorum.com/news/roches-tamiflu-successor-on-target-in-phase-3-trial/
ViiV’s Dovato HIV pill approved in EUViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over Share XViiV’s Dovato HIV pill approved in EUhttps://pharmaphorum.com/news/viivs-dovato-hiv-pill-approved-in-eu/
Dynavax cuts staff and cancer R&D, focuses on vaccineUS biotech Dynavax has announced staff cutbacks after deciding to focus on its vaccine business, while winding down Share XDynavax cuts staff and cancer R&D, focuses on vaccinehttps://pharmaphorum.com/news/dynavax-cuts-staff-and-cancer-rd-focuses-on-vaccine/
Gilead faces lawsuit over HIV drug pricingGilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving Share XGilead faces lawsuit over HIV drug pricinghttps://pharmaphorum.com/news/gilead-faces-lawsuit-over-hiv-drug-pricing/
